The stock market did well for Anthem Biosciences, a Bengaluru-based business that helps create and develop medications. On both the NSE and BSE, its shares started 27% higher. This implies that a lot of investors have faith in the company’s future and strength. A variety of different kinds of investors were interested in the IPO. Anthem Biosciences is off to a wonderful start because it has a lot of backing and a nice place in the market. This robust listing shows that people believe in its growth, its sound plans, and the expanding need for health and pharmaceutical products.
Performance on Listing Day
Anthem Biosciences’ shares started trading at ₹887.50 on the NSE and ₹875 on the BSE on the first day. This was a lot more than the IPO price of ₹655, which meant that early investors made about 27.4% on NSE and 25.2% on BSE. The stock was busy all day and traded a lot.
Investors were quite interested in the IPO before. There were more than 52 subscriptions for it. Big investors (QIBs) were the most interested, followed by NIIs and retail investors (RIIs).
The IPO’s details
Anthem Biosciences started its initial public offering (IPO) in early July to raise over ₹3,290 crore. This included ₹1,000 crore from a new issue and the balance from an offer for sale (OFS), in which current investors sold some of their shares.
The company wants to use the money from the new issue for three primary things to pay off debts, to satisfy working capital needs, and to grow its capacity. It will also put a lot of money into expanding its research and development and manufacturing operations, especially in biologics, to fulfil the growing demand around the world.
Strong Business and Growth Ahead
Anthem Biosciences was founded in 2007. It operates in the quickly increasing CDMO business and serves drug and biotech companies all around the world. The company helps with every phase of developing drugs, from early research to complete manufacture.
It provides a lot of help with both biology and chemistry. Making powerful APIs (active drug ingredients), peptides, and biologics is one of these. Anthem created a solid and linked business model over time.
Anthem has a lot of big drug companies as clients these days. The company is different from others in the CDMO industry because it meets all international laws and is continuously getting better.
Anthem’s company is developing quickly. It made more than ₹1,200 crore in sales in 2024 and preserved its high profit margins. Experts suggest that the company’s big setup, high-profit items, and strong global customer base will help it grow even more in the future.
Market Opinion and Analyst Thoughts
Experts remarked that Anthem Biosciences’ strong initial public offering (IPO) matched their expectations. People think positively about the outsourcing sector for pharmaceuticals and biotechnology, which is why this happened. The CDMO sector in India is growing quickly because corporations around the world desire cheap research and manufacturing services.
Many global pharmaceutical companies opt to do business in India because it has a lot of skilled scientists and strict regulations.
Many experts believe that Anthem may do well in the biologics and biosimilars market, which will get a lot bigger in the next few years.
Experts also praised Anthem for its clear long-term intentions and careful spending. They liked that the company is growing to focus on certain, high-profit sectors of healthcare. This implies that you have thought ahead.
Interest from investors and growth in the future
Investors are confident in Anthem Biosciences’ future, as shown by the strong response to its IPO. A lot of investors think Anthem is an excellent long-term investment, not just a way to make money quickly. This is because the company follows all the standards, concentrates on new ideas, and continually gets into new areas of medicine.
The global CDMO market is predicted to expand by more than 10% every year. This growth is due to more pharmaceutical companies outsourcing their work, patents running out, and a rising demand for biologics. Anthem has the proper tools and skills to take advantage of this trend.
The business also maintains spending money on eco-friendly procedures, automation, and digital technologies. These actions can help it work better and meet ESG (Environmental, Social, and Governance) criteria. Big investors are paying more and more attention to these things.
End Note
The 27% rise in Anthem Biosciences’ stock price illustrates that investors believe in its ambitions for development and sound business model. Anthem is in a good position to grow because demand for CDMO services is rising around the world. IPO investors see early gains, while long-term investors view it as a strong opportunity in a fast-growing, innovation-driven Indian life sciences sector.
About The Author
